ADIL Stock Analysis: Buy, Sell, or Hold?
ADIL - Adial Pharmaceuticals, Inc
$5.82
0.42 (7.78%)
▲
5d:
+6.79%
30d:
+107.12%
90d:
+159.82%
WAIT
LOW Confidence
Analysis Updated: Aug 25, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When ADIL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ADIL is 13.0% above its trading range ($5.15). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ADIL is 13.0% above its trading range ($5.15). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: ADIL is currently trading at $5.82, which is considered extended relative to its 30-day fair value range of $2.92 to $5.15.
Technical Outlook: Technically, ADIL is in a strong uptrend. Immediate support is located at $3.84, while resistance sits at $6.41. The stock is showing strong short-term momentum, up 7.8% recently.
Market Sentiment: ADIL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.33 (+43.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ADIL is in a strong uptrend. Immediate support is located at $3.84, while resistance sits at $6.41. The stock is showing strong short-term momentum, up 7.8% recently.
Market Sentiment: ADIL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.33 (+43.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.92 -
$5.15
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+13.0% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.8%)
- BULLISH: Trading 43.2% below Wall St target ($8.33)
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.92 -
$5.15
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.84
Resistance Level
$6.41
Current Trend
Strong Uptrend
Technical data as of
Aug 25, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.78
Wall Street Target
$8.33
(+43.2%)
Share & Embed Analysis
Last updated: August 25, 2026 8:24 PM ET
Data refreshes hourly during market hours. Next update: 9:24 PM
Data refreshes hourly during market hours. Next update: 9:24 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADIL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 67 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 36 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 39 SELL |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 55 HOLD |
